AstraZeneca to launch cancer drug Acalabrutinib under brand name Calquence

Written by Ruchika Sharma Published On 2020-10-16T11:25:25+05:30 | Updated On 16 Oct 2020 11:25 AM IST

New Delhi: Drug firm AstraZeneca Pharma India on Thursday said it will launch its Acalabrutinib 100 mg capsules, used for treatment of various types of blood cancers, under the brand name ''Calquence'' in the country on October 21.

The capsules are indicated for treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy and for treatment of patients with chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL), AstraZeneca Pharma India said in a filing to the BSE.

astrazenecaastrazeneca newsacalabrutinib capsulesblood cancercalquence

Source : PTI

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751